Last reviewed · How we verify

Psychopharmacotherapy in Multiple Substances Abuse / Dependence - the Pharmacological and Immunological Approach to the New Indication of Memantine (MM opioid)

NCT01189214 Phase 3 COMPLETED

Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.

Details

Lead sponsorNational Cheng-Kung University Hospital
PhasePhase 3
StatusCOMPLETED
Enrolment200
Start date2009-03
Completion2011-06

Conditions

Interventions

Primary outcomes

Countries

Taiwan